busulfan has been researched along with Central Nervous System Neoplasm in 27 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thiotepa, busulfan and cyclophosphamide-based intensive chemotherapy is an effective treatment for refractory and recurrent primary central nervous system lymphoma in chemosensitive patients up to 65 years of age." | 9.16 | Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma: a retrospective study of 79 cases. ( Bouabdallah, K; Choquet, S; Damaj, G; Delgadillo, D; Dupriez, B; Fourme, E; Ghesquières, H; Gonzalez, A; Hoang-Xuan, K; Houillier, C; Leblond, V; Soussain, C; Taillandier, L; Vargaftig, J, 2012) |
| " BU, CY and etoposide (BUCYE), followed by auto-SCT (ASCT) in patients with newly diagnosed primary central nervous system lymphoma (PCNSL)." | 9.15 | Feasibility of BU, CY and etoposide (BUCYE), and auto-SCT in patients with newly diagnosed primary CNS lymphoma: a single-center experience. ( Choi, DR; Huh, J; Kim, S; Kim, SW; Lee, DH; Lee, JS; Lee, SW; Sohn, BS; Suh, C; Yoon, DH, 2011) |
| "We investigated the efficacy and safety of tandem high-dose methotrexate (HD-MTX) induction followed by high-dose busulfan/thiotepa (HD-BuTT) with autologous peripheral blood stem-cell transplantation (aPBSCT) and response-adapted whole-brain radiation therapy (WBRT) in patients with newly diagnosed primary central nervous system lymphoma." | 9.12 | Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkol ( Al-Ali, HK; Dölken, G; Haas, A; Helke, K; Herbst, R; Hirt, C; Kiefer, T; Krüger, WH; Lotze, C; Montemurro, M; Niederwieser, D; Schüler, F; Schwenke, M; Theilig, A; Wolf, HH, 2007) |
| "A retrospective analysis was performed of 48 consecutive patients who had undergone HDC/ASCT with TBC (thiotepa, busulfan, cyclophosphamide) conditioning for PCNSL (27 patients), secondary CNS lymphoma (SCNSL) (8 patients), or relapsed disease with CNS involvement (13 patients) from July 2006 to December 2017." | 7.96 | Durable Survival Outcomes in Primary and Secondary Central Nervous System Lymphoma After High-dose Chemotherapy and Autologous Stem Cell Transplantation Using a Thiotepa, Busulfan, and Cyclophosphamide Conditioning Regimen. ( Chute, J; de Vos, S; Eradat, HA; Gaut, D; Grotts, J; Kimaiyo, DK; Romero, T; Schiller, G; Timmerman, J; Young, PA, 2020) |
| "We investigated the incidence of viral, fungal, bacterial, and parasitic infections observed in 57 patients with central nervous system lymphoma after thiotepa, busulfan, and cyclophosphamide-conditioned autologous stem cell transplantation (TBC-ASCT) and 79 patients with systemic non-Hodgkin lymphoma after traditional carmustine, etoposide, cytarabine, and melphalan-conditioned ASCT (BEAM-ASCT)." | 7.88 | Distinctive Infectious Complications in Patients with Central Nervous System Lymphoma Undergoing Thiotepa, Busulfan, and Cyclophosphamide-conditioned Autologous Stem Cell Transplantation. ( Bhatia, A; Chung, HH; DeAngelis, LM; Giralt, SA; Littmann, ER; Maloy, M; Morjaria, SM; Sauter, CS; Scordo, M; Taur, Y, 2018) |
| "High-dose therapy and autologous stem cell transplantation (ASCT) with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning has emerged as an effective postinduction treatment strategy for patients with primary central nervous system lymphoma (PCNSL) or secondary central nervous system lymphoma (SCNSL), but it is associated with considerable toxicity and transplantation-related mortality (TRM) in the modern era." | 7.85 | A Comprehensive Assessment of Toxicities in Patients with Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using Thiotepa, Busulfan, and Cyclophosphamide Conditioning. ( Bhatt, V; Dahi, PB; DeAngelis, LM; Giralt, SA; Hsu, M; Matasar, MJ; Moskowitz, CH; Omuro, AM; Sauter, CS; Scordo, M, 2017) |
| "The aim of this study was to evaluate the efficacy and toxicity of two chemotherapy regimens based on platinum and cytarabine in association with etoposide and methylprednisolone (ESHAP) or with dexamethasone (DHAP) with or without Rituximab (± R) in patients with refractory or a relapsed Primary Central Nervous System Lymphoma (PCNSL)." | 7.77 | Platine and cytarabine-based salvage treatment for primary central nervous system lymphoma. ( Choquet, S; del Rio, MS; Fourme, E; Glaisner, S; Hoang-Xuan, K; Janvier, M; Soussain, C, 2011) |
| "Thiotepa, busulfan and cyclophosphamide-based intensive chemotherapy is an effective treatment for refractory and recurrent primary central nervous system lymphoma in chemosensitive patients up to 65 years of age." | 5.16 | Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma: a retrospective study of 79 cases. ( Bouabdallah, K; Choquet, S; Damaj, G; Delgadillo, D; Dupriez, B; Fourme, E; Ghesquières, H; Gonzalez, A; Hoang-Xuan, K; Houillier, C; Leblond, V; Soussain, C; Taillandier, L; Vargaftig, J, 2012) |
| " BU, CY and etoposide (BUCYE), followed by auto-SCT (ASCT) in patients with newly diagnosed primary central nervous system lymphoma (PCNSL)." | 5.15 | Feasibility of BU, CY and etoposide (BUCYE), and auto-SCT in patients with newly diagnosed primary CNS lymphoma: a single-center experience. ( Choi, DR; Huh, J; Kim, S; Kim, SW; Lee, DH; Lee, JS; Lee, SW; Sohn, BS; Suh, C; Yoon, DH, 2011) |
| "We investigated the efficacy and safety of tandem high-dose methotrexate (HD-MTX) induction followed by high-dose busulfan/thiotepa (HD-BuTT) with autologous peripheral blood stem-cell transplantation (aPBSCT) and response-adapted whole-brain radiation therapy (WBRT) in patients with newly diagnosed primary central nervous system lymphoma." | 5.12 | Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkol ( Al-Ali, HK; Dölken, G; Haas, A; Helke, K; Herbst, R; Hirt, C; Kiefer, T; Krüger, WH; Lotze, C; Montemurro, M; Niederwieser, D; Schüler, F; Schwenke, M; Theilig, A; Wolf, HH, 2007) |
| "A retrospective analysis was performed of 48 consecutive patients who had undergone HDC/ASCT with TBC (thiotepa, busulfan, cyclophosphamide) conditioning for PCNSL (27 patients), secondary CNS lymphoma (SCNSL) (8 patients), or relapsed disease with CNS involvement (13 patients) from July 2006 to December 2017." | 3.96 | Durable Survival Outcomes in Primary and Secondary Central Nervous System Lymphoma After High-dose Chemotherapy and Autologous Stem Cell Transplantation Using a Thiotepa, Busulfan, and Cyclophosphamide Conditioning Regimen. ( Chute, J; de Vos, S; Eradat, HA; Gaut, D; Grotts, J; Kimaiyo, DK; Romero, T; Schiller, G; Timmerman, J; Young, PA, 2020) |
| "Autologous stem cell transplantation (ASCT) with high-dose thiotepa and busulfan is a treatment option for patients with central nervous system (CNS) lymphoma." | 3.96 | Secondary failure of platelet recovery in patients treated with high-dose thiotepa and busulfan followed by autologous stem cell transplantation. ( Aiba, A; Hishizawa, M; Kitano, T; Kondo, T; Nishikori, M; Shimazu, Y; Shindo, T; Takaori-Kondo, A; Wada, F; Watanabe, M, 2020) |
| "We investigated the incidence of viral, fungal, bacterial, and parasitic infections observed in 57 patients with central nervous system lymphoma after thiotepa, busulfan, and cyclophosphamide-conditioned autologous stem cell transplantation (TBC-ASCT) and 79 patients with systemic non-Hodgkin lymphoma after traditional carmustine, etoposide, cytarabine, and melphalan-conditioned ASCT (BEAM-ASCT)." | 3.88 | Distinctive Infectious Complications in Patients with Central Nervous System Lymphoma Undergoing Thiotepa, Busulfan, and Cyclophosphamide-conditioned Autologous Stem Cell Transplantation. ( Bhatia, A; Chung, HH; DeAngelis, LM; Giralt, SA; Littmann, ER; Maloy, M; Morjaria, SM; Sauter, CS; Scordo, M; Taur, Y, 2018) |
| "High-dose therapy and autologous stem cell transplantation (ASCT) with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning has emerged as an effective postinduction treatment strategy for patients with primary central nervous system lymphoma (PCNSL) or secondary central nervous system lymphoma (SCNSL), but it is associated with considerable toxicity and transplantation-related mortality (TRM) in the modern era." | 3.85 | A Comprehensive Assessment of Toxicities in Patients with Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using Thiotepa, Busulfan, and Cyclophosphamide Conditioning. ( Bhatt, V; Dahi, PB; DeAngelis, LM; Giralt, SA; Hsu, M; Matasar, MJ; Moskowitz, CH; Omuro, AM; Sauter, CS; Scordo, M, 2017) |
| "The aim of this study was to evaluate the efficacy and toxicity of two chemotherapy regimens based on platinum and cytarabine in association with etoposide and methylprednisolone (ESHAP) or with dexamethasone (DHAP) with or without Rituximab (± R) in patients with refractory or a relapsed Primary Central Nervous System Lymphoma (PCNSL)." | 3.77 | Platine and cytarabine-based salvage treatment for primary central nervous system lymphoma. ( Choquet, S; del Rio, MS; Fourme, E; Glaisner, S; Hoang-Xuan, K; Janvier, M; Soussain, C, 2011) |
| "Lymphopenia was also a significant prognostic factor for progression-free survival (HR 3." | 1.43 | A new prognostic model using absolute lymphocyte count in patients with primary central nervous system lymphoma. ( Cheong, JW; Cho, H; Chung, H; Jang, JE; Kim, JS; Kim, SJ; Kim, Y; Kim, YR; Lee, JY; Min, YH; Park, H, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (14.81) | 29.6817 |
| 2010's | 18 (66.67) | 24.3611 |
| 2020's | 5 (18.52) | 2.80 |
| Authors | Studies |
|---|---|
| Schenone, L | 1 |
| Houillier, C | 2 |
| Tanguy, ML | 1 |
| Choquet, S | 3 |
| Agbetiafa, K | 1 |
| Ghesquières, H | 2 |
| Damaj, G | 2 |
| Schmitt, A | 1 |
| Bouabdallah, K | 2 |
| Ahle, G | 1 |
| Gressin, R | 1 |
| Cornillon, J | 1 |
| Houot, R | 1 |
| Marolleau, JP | 1 |
| Fornecker, LM | 1 |
| Chinot, O | 1 |
| Peyrade, F | 1 |
| Bouabdallah, R | 1 |
| Moluçon-Chabrot, C | 1 |
| Gyan, E | 1 |
| Chauchet, A | 1 |
| Casasnovas, O | 1 |
| Oberic, L | 1 |
| Delwail, V | 1 |
| Abraham, J | 1 |
| Roland, V | 1 |
| Waultier-Rascalou, A | 1 |
| Willems, L | 1 |
| Morschhauser, F | 1 |
| Fabbro, M | 1 |
| Ursu, R | 1 |
| Thieblemont, C | 1 |
| Jardin, F | 1 |
| Tempescul, A | 1 |
| Malaise, D | 1 |
| Touitou, V | 1 |
| Nichelli, L | 1 |
| Le Garff-Tavernier, M | 1 |
| Plessier, A | 1 |
| Bourget, P | 1 |
| Bonmati, C | 1 |
| Wantz-Mézières, S | 1 |
| Giordan, Q | 1 |
| Dorvaux, V | 1 |
| Charron, C | 1 |
| Jabeur, W | 1 |
| Hoang-Xuan, K | 5 |
| Taillandier, L | 2 |
| Soussain, C | 5 |
| Puckrin, R | 1 |
| Chua, N | 3 |
| Shafey, M | 2 |
| Stewart, DA | 5 |
| Kaulen, LD | 1 |
| Baehring, JM | 1 |
| Young, PA | 1 |
| Gaut, D | 1 |
| Kimaiyo, DK | 1 |
| Grotts, J | 1 |
| Romero, T | 1 |
| Chute, J | 1 |
| Schiller, G | 1 |
| de Vos, S | 1 |
| Eradat, HA | 1 |
| Timmerman, J | 1 |
| Wada, F | 1 |
| Nishikori, M | 1 |
| Hishizawa, M | 1 |
| Watanabe, M | 1 |
| Aiba, A | 1 |
| Kitano, T | 1 |
| Shimazu, Y | 1 |
| Shindo, T | 1 |
| Kondo, T | 1 |
| Takaori-Kondo, A | 1 |
| DeFilipp, Z | 1 |
| Li, S | 2 |
| El-Jawahri, A | 1 |
| Armand, P | 3 |
| Nayak, L | 2 |
| Wang, N | 1 |
| Batchelor, TT | 2 |
| Chen, YB | 3 |
| Hamidieh, AA | 1 |
| Monzavi, SM | 1 |
| Kaboutari, M | 1 |
| Behfar, M | 1 |
| Esfandbod, M | 1 |
| Scordo, M | 2 |
| Morjaria, SM | 1 |
| Littmann, ER | 1 |
| Bhatia, A | 1 |
| Chung, HH | 1 |
| Maloy, M | 1 |
| DeAngelis, LM | 3 |
| Giralt, SA | 2 |
| Taur, Y | 1 |
| Sauter, CS | 4 |
| Sanders, S | 1 |
| Larouche, JF | 1 |
| Owen, C | 2 |
| Hyung, J | 1 |
| Hong, JY | 1 |
| Yoon, DH | 2 |
| Kim, S | 2 |
| Park, JS | 1 |
| Park, CS | 1 |
| Lee, SW | 2 |
| Kim, JH | 1 |
| Ryu, JS | 1 |
| Huh, J | 2 |
| Suh, C | 2 |
| Welch, MR | 1 |
| Matasar, MJ | 3 |
| Faivre, G | 2 |
| Weaver, SA | 1 |
| Moskowitz, CH | 3 |
| Omuro, AM | 2 |
| Batchelor, T | 1 |
| Hochberg, E | 1 |
| Brezina, M | 1 |
| Jones, S | 1 |
| Del Rio, C | 1 |
| Curtis, M | 1 |
| Ballen, KK | 1 |
| Barnes, J | 1 |
| Chi, AS | 1 |
| Dietrich, J | 1 |
| Driscoll, J | 1 |
| Gertsner, ER | 1 |
| Hochberg, F | 1 |
| LaCasce, AS | 2 |
| McAfee, SL | 2 |
| Spitzer, TR | 1 |
| Omuro, A | 1 |
| Correa, DD | 1 |
| Kaley, TJ | 1 |
| Gavrilovic, IT | 1 |
| Nolan, C | 1 |
| Pentsova, E | 1 |
| Grommes, CC | 1 |
| Panageas, KS | 1 |
| Baser, RE | 1 |
| Abrey, LE | 1 |
| Oh, DH | 1 |
| Street, L | 1 |
| Lee, MY | 1 |
| Kim, HS | 1 |
| Lee, JY | 2 |
| Lim, SH | 1 |
| Kang, ES | 1 |
| Ko, YH | 1 |
| Kim, SJ | 2 |
| Kim, WS | 1 |
| Jang, JE | 1 |
| Kim, YR | 1 |
| Cho, H | 1 |
| Chung, H | 1 |
| Park, H | 1 |
| Kim, Y | 1 |
| Cheong, JW | 1 |
| Min, YH | 1 |
| Kim, JS | 1 |
| Bhatt, V | 1 |
| Hsu, M | 1 |
| Dahi, PB | 1 |
| Lee, DH | 1 |
| Choi, DR | 1 |
| Sohn, BS | 1 |
| Kim, SW | 1 |
| Lee, JS | 1 |
| Mayadev, JS | 1 |
| Douglas, JG | 1 |
| Storer, BE | 1 |
| Appelbaum, FR | 1 |
| Storb, R | 1 |
| del Rio, MS | 1 |
| Glaisner, S | 1 |
| Fourme, E | 2 |
| Janvier, M | 1 |
| Cote, GM | 1 |
| Hochberg, EP | 1 |
| Muzikansky, A | 1 |
| Hochberg, FH | 1 |
| Drappatz, J | 1 |
| Fisher, DC | 1 |
| Abramson, JS | 1 |
| Alimohamed, N | 1 |
| Daly, A | 1 |
| Duggan, P | 1 |
| Delgadillo, D | 1 |
| Dupriez, B | 1 |
| Vargaftig, J | 1 |
| Gonzalez, A | 1 |
| Leblond, V | 2 |
| Cheng, T | 1 |
| Forsyth, P | 1 |
| Chaudhry, A | 1 |
| Morris, D | 1 |
| Glück, S | 1 |
| Russell, JA | 1 |
| Levy, V | 2 |
| Montemurro, M | 1 |
| Kiefer, T | 1 |
| Schüler, F | 1 |
| Al-Ali, HK | 1 |
| Wolf, HH | 1 |
| Herbst, R | 1 |
| Haas, A | 1 |
| Helke, K | 1 |
| Theilig, A | 1 |
| Lotze, C | 1 |
| Hirt, C | 1 |
| Niederwieser, D | 1 |
| Schwenke, M | 1 |
| Krüger, WH | 1 |
| Dölken, G | 1 |
| Suzan, F | 1 |
| Cassoux, N | 1 |
| Azar, N | 1 |
| Belanger, C | 1 |
| Achour, E | 1 |
| Ribrag, V | 1 |
| Gerber, S | 1 |
| Delattre, JY | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Intensive Conditioning Regimen With Thiotepa Combined With Busulfan, Fludarabine and Cytarabine for Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Myeloid Malignancies With Extramedullary Involvement[NCT06111612] | 50 participants (Anticipated) | Observational | 2024-01-01 | Not yet recruiting | |||
| Phase II Trial of Hihg-Dose Thiotepa, Busulfan, Cyclophosphamide, and Rituximab With Autologous Stem Cell Transplantation for Patients With CNS Involvement by Non-Hodgkin's Lymphoma or Primary CNS Lymphoma[NCT01182415] | Phase 2 | 30 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| A Phase II， Single-arm Trail of Chidamide Combined With Rituximab and High-dose Methotrexate in Previously Untreated Patients With Primary Central Nervous System Lymphoma[NCT04516655] | Phase 2 | 51 participants (Anticipated) | Interventional | 2020-09-01 | Not yet recruiting | ||
| Rituximab, Methotrexate, Procarbazine and Vincristine Followed by High-dose Chemotherapy With Autologous Stem-cell Rescue in Newly-diagnosed Primary CNS Lymphoma (PCNSL)[NCT00596154] | Phase 2 | 33 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| A Phase 2a Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma[NCT01235793] | Phase 2 | 11 participants (Actual) | Interventional | 2010-10-14 | Terminated (stopped due to The clinical trial was terminated due to poor enrollment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The percentage of participants alive after two years (NCT01182415)
Timeframe: 2 years
| Intervention | percentage of participants (Number) |
|---|---|
| High-dose Chemotherapy With Autologous Stem Cell Transplant | 93 |
The percentage of participants alive and without disease progression at 2 years. Disease progression was judged through clinical impression and MRI imaging. (NCT01182415)
Timeframe: 2 years
| Intervention | percentage of participants (Number) |
|---|---|
| High-dose Chemotherapy With Autologous Stem Cell Transplant | 81 |
The proportion of patients with central nervous system (CNS) involvement by B-cell Non-Hodgkin's Lymphoma (NHL), relapsed primary central nervous system lymphoma (PCNSL), or relapsed primary intraocular lymphoma (PIOL) who are alive and progression-free at one year. Relapse was defined as per standard PCNSL criteria from clinical and MRI criteria. (NCT01182415)
Timeframe: 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| High-dose Chemotherapy With Autologous Stem Cell Transplant | 28 |
The number of participants that achieved complete remission following high dose chemotherapy and autologous stem cell transplantation (ASCT). Complete remission is defined as the disappearance of all evidence of disease. Response was judged by MRI assessment. (NCT01182415)
Timeframe: 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| High-dose Chemotherapy With Autologous Stem Cell Transplant | 29 |
Safety will be assessed using a dose escalation design for temozolomide's use to determine the target dose and also to evaluate any and all acute treatment related toxicities. During the course of patient follow up and therapy, toxicities will be evaluated, particularly as the investigators will be determining the target dose of temozolomide. One of the major criteria for dose limiting toxicity for the study will be any Grade 3 or 4 nonhematologic toxicity from a list of commonly expected toxicities associated with autologous transplantation and temozolomide. (NCT01235793)
Timeframe: One Year
| Intervention | dose in mg/m^2 (Number) |
|---|---|
| DRBEAT Regimen | 773.25 |
"Efficacy of the DRBEAT Regimen will be assessed by analysis of~one-year progression-free survival (PFS), defined as the time interval from maximal response from therapy to tumor regrowth, progression*, or death, (*Progression is defined as meeting the response criteria listed in Table 4: Response Criteria for Primary Central Nervous System Lymphoma according to Abrey LE, Batchelor TT, Ferreri AJM et al.)~and~Overall survival, defined as the time interval between the date of transplant and the date of death from any cause." (NCT01235793)
Timeframe: (1) One Year (2) Until date of death from any cause, assessed up to 2 years
| Intervention | Days (Median) | |
|---|---|---|
| Progression Free Survival | Overall Survival | |
| DRBEAT Regimen | 132 | 564 |
1 review available for busulfan and Central Nervous System Neoplasm
| Article | Year |
|---|---|
Treatment Options for Recurrent Primary CNS Lymphoma.
Topics: Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms | 2022 |
8 trials available for busulfan and Central Nervous System Neoplasm
| Article | Year |
|---|---|
Outcomes of Consecutively Diagnosed Primary Central Nervous System Lymphoma Patients Using the Alberta Lymphoma Clinical Practice Guideline Incorporating Thiotepa-Busulfan Conditioning for Transplantation-Eligible Patients.
Topics: Adult; Aged; Aged, 80 and over; Alberta; Autografts; Busulfan; Central Nervous System Neoplasms; Dis | 2019 |
Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2015 |
R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2015 |
R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2015 |
R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2015 |
Feasibility of BU, CY and etoposide (BUCYE), and auto-SCT in patients with newly diagnosed primary CNS lymphoma: a single-center experience.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Centra | 2011 |
Upfront thiotepa, busulfan, cyclophosphamide, and autologous stem cell transplantation for primary CNS lymphoma: a single centre experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cause of Death; Central Nervo | 2012 |
Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma: a retrospective study of 79 cases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neopla | 2012 |
Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkol
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous S | 2007 |
Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neoplasms; C | 2001 |
18 other studies available for busulfan and Central Nervous System Neoplasm
| Article | Year |
|---|---|
Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life-experience of the French Network.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Central Nervous System; Centra | 2022 |
Improving the outcomes of secondary CNS lymphoma with high-dose thiotepa, busulfan, melphalan, rituximab conditioning and autotransplant.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Busulfan; Central Nervous S | 2022 |
Durable Survival Outcomes in Primary and Secondary Central Nervous System Lymphoma After High-dose Chemotherapy and Autologous Stem Cell Transplantation Using a Thiotepa, Busulfan, and Cyclophosphamide Conditioning Regimen.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neoplasms; Cy | 2020 |
Secondary failure of platelet recovery in patients treated with high-dose thiotepa and busulfan followed by autologous stem cell transplantation.
Topics: Adult; Aged; Busulfan; Central Nervous System Neoplasms; Female; Hematopoietic Stem Cell Transplanta | 2020 |
High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Busulfan; Central | 2017 |
Outcome Analysis of Pediatric Patients with Acute Lymphoblastic Leukemia Treated with Total Body Irradiation-Free Allogeneic Hematopoietic Stem Cell Transplantation: Comparison of Patients with and Without Central Nervous System Involvement.
Topics: Adolescent; Busulfan; Central Nervous System Neoplasms; Child; Child, Preschool; Cross-Sectional Stu | 2017 |
Distinctive Infectious Complications in Patients with Central Nervous System Lymphoma Undergoing Thiotepa, Busulfan, and Cyclophosphamide-conditioned Autologous Stem Cell Transplantation.
Topics: Busulfan; Central Nervous System Neoplasms; Cyclophosphamide; Female; Humans; Lymphoma; Male; Middle | 2018 |
Thiotepa, busulfan, and cyclophosphamide or busulfan, cyclophosphamide, and etoposide high-dose chemotherapy followed by autologous stem cell transplantation for consolidation of primary central nervous system lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Busulfan; Central Nervous System N | 2019 |
Autologous stem cell transplant in recurrent or refractory primary or secondary central nervous system lymphoma using thiotepa, busulfan and cyclophosphamide.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neopla | 2015 |
Treatment of patients with secondary central nervous system lymphoma with high-dose busulfan/thiotepa-based conditioning and autologous stem cell transplant.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neoplasms; Combined | 2016 |
Efficacy and feasibility of autologous stem cell transplantation in patients with diffuse large B‑cell lymphoma with secondary central nervous system involvement.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autografts; Busulfan; Central Nervous System Neoplas | 2015 |
A new prognostic model using absolute lymphocyte count in patients with primary central nervous system lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neopla | 2016 |
A Comprehensive Assessment of Toxicities in Patients with Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using Thiotepa, Busulfan, and Cyclophosphamide Conditioning.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neopla | 2017 |
Impact of cranial irradiation added to intrathecal conditioning in hematopoietic cell transplantation in adult acute myeloid leukemia with central nervous system involvement.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous S | 2011 |
Platine and cytarabine-based salvage treatment for primary central nervous system lymphoma.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combin | 2011 |
Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neopla | 2012 |
High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Busulfan; | 2003 |
[Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neopla | 2004 |